---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-004784"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2025-06-27T23:59:59+00:00"
generated_at: "2026-05-18T17:10:50.080625+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients

## Summary
- Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.
- First three patients treated in Hemopurifier cancer trial in Australia; DSMB safety review triggered.
- Received Indian regulatory approval (CDSCO) to initiate similar oncology trial at Medanta Medicity Hospital.
- Preclinical study showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier treatment.
- Non-cash warrant inducement charge of $4.6M; ERTC other income $324,450.

## SEC filing metadata
- accession: 0001683168-25-004784
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2025-06-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/0001683168-25-004784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/aemd_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-004784
- JSON: https://secwatch.observer/filing/0001683168-25-004784.json
- Plain text: https://secwatch.observer/filing/0001683168-25-004784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.